CureTalks@Penn Research Interviews

Despite advancements in understanding the initial cancer development, the factors driving recurrence of BRCA related breast and ovarian cancers remain elusive, posing a significant challenge in managing the long-term health of mutation carriers.

Fewer than 1000 people in the US have Lecithin cholesterol acyltransferase (LCAT) deficiency. We are speaking with Dr. Marina Cuchel from University of Pennsylvania to understand the condition better.

Dr. Mathias Basner of University of Pennsylvania, studies astronaut behavioral health on long-duration space missions will be discussing various effects of microgravity on human health, cognition, and behavior.

We are speaking with Dr. Amit Bar-Or, director of the Penn MS program to learn about the advances made in diagnosis and treatment of MS and understand how precision medicine can improve quality of life for MS patients.

Mild or moderate COVID-19 lasts for up to 2 weeks for most people. However, many who recovered from the initial infection of COVID-19 and tested negative continue to experience some long-term after effects of the disease.

Schizophrenia is one of the top 15 leading causes of disability throughout the world. We are talking to Dr Monica E. Calkins, Associate Professor of Psychology in Psychiatry at the University of Pennsylvania, to explore early indicators and discuss advances in early identification, prevention and finding more effective treatment of schizophrenia.

We are talking to Dr. Emma A. Meagher, Professor, Medicine and Pharmacology, Vice Dean, Perelman School of Medicine, University of Pennsylvania and VP of University of Pennsylvania Health System, about the basics of clinical research

We are speaking with Dr Andres F. Deik of University of Pennsylvania to learn about the basics of managing Parkinson's disease, available treatment approaches and clinical trials in Parkinson's disease.

Teclistamab is a bispecific IgG4 antibody that binds BCMA and CD3 to redirect T cells to multiple myeloma cells. According to the investigators, the current study is — to their knowledge — the first report of a T-cell — redirecting bispecific antibody for the treatment of patients with cancer.

Progress in antiretroviral therapy has considerably reduced mortality and notably improved the quality of life of individuals infected with HIV. However, drug resistance, treatment-associated toxicity, adherence to medication, and the need for lifelong therapy have remained major challenges. While the development of an HIV vaccine has remained elusive, considerable progress in developing innovative cell and gene therapies to treat HIV infection has been made.